20633-35-6

Upstream product

• 107-21-1 ethylene glycol 
• 288296-72-0 2-(4-chloro-1,1-dimethylbutyl)-1,3-dioxolane 

Downstream Products

• 13395-71-6 2,4,4-trimethyl-2-cyclohexenone 
• 250348-03-9 rac-6-isopropyl-3,3-dimethyl-3,4,5,6-tetrahydropyridine 
• 250348-04-0 rac-3,3-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridine 
• 93737-24-7 1,1,3-Trimethyl-2-benzoylmethyl-cyclohexen-3 
• 472-64-0 (2,6,6-Trimethyl-2-cyclohexenyl)acetaldehyde 
• 288295-80-7 tert-butyl N-(1S,2R)-1-benzyl-3-[(5-cyano-2,2-dimethylpentyl)amino]-2-hydroxypropylcarbamate 
• 288291-54-3 1,3-Dioxan-5-yl N-[(1S,2R)-1-benzyl-3-((4-cyano-2,2-dimethylbutyl)[3-(methylamino)phenyl]sulfonylamino)-2-hydroxypropyl]carbamate 
• 261917-70-8 3,3-Dimethyl-6,6-diphenyl-3,4,5,6-tetrahydropyridine 
• 250347-98-9 4-[1,3]dioxolan-2-yl-4-methyl-1-phenyl-pentylamine 

Relevant academic research and scientific papers

Inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

The synthesis of novel cyclic β-amino acids as intermediates for the preparation of bicyclic β-lactams

Several derivatives of homopipecolic acid are prepared by α-amino alkylation of malonic acid with cyclic imines 6 and 7. These are prepared on a large scale and with different substitution patterns. The β-amino acids 8 and 9 were formed in high yield and with remarkable diastereoselectivity if chiral imines are used as starting materials. The diastereoselectivity of the amino alkylation leading to homopipecolic acid analogues is compared to those of thiazolidineacetic acids by epimerisation experiments. A method for resolution of the obtained racemic β-amino acids by diastereomeric salt formation is described. The β-amino acids 9 and 15 were converted into their corresponding carbacepham analogues 14 and isopenam 16. The isopenam endo-16 was selectively epimerised by mild basic treatment of the N/S-acetal to give an exo-configured precursor of isopenicillin G.